News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Should Head Back to the Acquisition Trail, Abbvie or Bristol-Myers Squibb Canada (BMY) Should be Targeted: Analyst



9/28/2012 8:32:29 AM

Roche Holding AG grabbed several headlines earlier this year when it launched -- and ultimately withdrew -- a $6.3 billion bid for Illumina Inc., but one prominent analyst has identified two potential targets that the pharma giant should now consider. In a research note Wednesday, Sept. 26, Jefferies & Co. analyst Jeffrey Holford identified both AbbVie -- the pharmaceutical business Abbott Laboratories will spin out Jan. 1, 2013 -- and Bristol-Myers Squibb Co. as two prime strategic assets for Roche to acquire.

Read at The Deal.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES